Destiny releases pivotal phase 2 data involving XF-73 nasal gel
Study shows significant reduction of nasal S. aureus in cardiac surgery patients before surgery
Read More
Tag: XF-73
Destiny Pharma listed on London Stock Exchange
Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in the UK.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
